Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRX215 in Participants After Hepatectomy Due to Colon Carcinoma Metastases
NCT06638502Phase 2Recruiting
- Sponsor
- HepaRegeniX GmbH
- Start
- May 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of darizmetinib in colorectal carcinoma (CRC) (4 arms), sponsored by HepaRegeniX GmbH. Primary endpoints: Adverse Events at 6 months and HRX215 plasma levels at 28 days. Started May 2025; status: recruiting.
02
Drugs
darizmetinib
03
Conditions
colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT06638502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06638502.